Global Cervical Cancer Diagnostic Testing Market Analysis: Test Types, Growth Trends and Forecast to 2020

The global cervical cancer diagnostic testing market is estimated to reach USD 8.5 Billion in 2020, expanding at a CAGR of 5.5% from 2016 to 2020, due to higher incidence of human papillomavirus (HPV) infections worldwide. Pap smear tests and colposcopy contributed to the largest share of the global cervical cancer diagnostic testing market, while HPV typing segment registered highest growth rate. By geography, North America dominated the overall market growth followed by Europe, while Asia Pacific region registered higher growth rate and likely continue to the same during the forecast period from 2016-2020.

Browse Cervical Cancer Diagnostic Testing Market by Test Type (Cervical Biopsy, Colposcopy, Endocervical Curettage, HPV Typing, Loop electrosurgical procedure, Pap Smear Testing), and Imaging Tests for Stage Detection (Computed tomography or CAT, Magnetic resonance imaging, Positron emission tomography, Chest X-Ray) 2016-2020 at https://www.ihealthcareanalyst.com/report/cervical-cancer-diagnostic-testing-market/

Cervical cancer is one of the most common cancers in women worldwide. Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus or HPV. The virus spreads through sexual contact. It is a malignant tumor of the lower most part of the uterus (womb) that can be prevented by PAP smear screening and a HPV vaccine. Cervical cancer is the fourth-most common cause of cancer and the fourth-most common cause of deaths from cancer in women. Two major types of cervical cancers that are typically screened and diagnosed in women include adenocarcinoma and squamous cell carcinoma. The Pap test is a screening test, not a diagnostic test, while other tests include colposcopy (with biopsy), endocervical scraping, and cone biopsies. Imaging tests such as X-rays, CT scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) help determine the spread of cancer.

The global cervical cancer diagnostic testing market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on diagnostic test type (cervical biopsy, colposcopy, endocervical curettage, HPV typing, Loop electrosurgical procedure, pap smear testing, and imaging tests for stage detection such as Computed tomography or CAT, Magnetic resonance imaging, Positron emission tomography, chest X-ray, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global cervical cancer diagnostic testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global cervical cancer diagnostic testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global cervical cancer diagnostic testing market and included in this report are Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., and OncoHealth Corp.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/cervical-cancer-diagnostic-testing-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 500-7508
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.